Table 3.
Maraviroc Switch Study Virological Outcomes: 48-Week Data
| Analysis | Arm | Below Threshold, % | Difference, % | (95% CI) |
|---|---|---|---|---|
| Intention to treat | ||||
| <50 copies/mL | Control | 95.1 | Reference | |
| MVC + 2 N(t)RTIs | 91.7 | −3.5 | (−9.6 to 3.8) | |
| MVC + PI/r | 77.7 | −17.4 | (−24.9 to −8.4) | |
| <200 copies/mL | Control | 97.6 | Reference | |
| MVC + 2 N(t)RTIs | 93.6 | −4.0 | (−9.0 to 2.2) | |
| MVC + PI/r | 84.1 | −13.5 | (−19.8 to −5.8) | |
| Noncompletion = failure | ||||
| <50 copies/mL | Control | 93.9 | Reference | |
| MVC + 2 N(t)RTIs | 87.2 | −6.7 | (−13.8 to 1.5) | |
| MVC + PI/r | 74.5 | −19.4 | (−27.4 to −9.9) | |
| <200 copies/mL | Control | 96.3 | Reference | |
| MVC + 2 N(t)RTIs | 88.5 | −7.9 | (−14.1 to −.4) | |
| MVC + PI/r | 80.3 | −16.1 | (−23.1 to −7.6) | |
| Per-protocol | ||||
| <50 copies/mL | Control | 96.3 | Reference | |
| MVC + 2 N(t)RTIs | 97.1 | 0.9 | (−4.2 to 6.9) | |
| MVC + PI/r | 83.6 | −12.7 | (−19.8 to −4.3) | |
| <200 copies/mL | Control | 98.8 | Reference | |
| MVC + 2 N(t)RTIs | 98.6 | −0.2 | (−3.8 to 4.4) | |
| MVC + PI/r | 90 | −8.8 | (−14.2 to −2.1) | |
Abbreviations: CI, confidence interval; MVC, maraviroc; N(t)RTI, nucleoside/nucleotide reverse transcriptase inhibitor; PI/r, ritonavir-boosted protease inhibitor.